Defying malaria: Arming T cells to halt malaria.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

14 citing papers in PubMed.

1. Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure.PloS one · 2014
   Trial
2. Assessment of immune interference, antagonism, and diversion following human immunization with biallelic blood-stage malaria viral-vectored vaccines and controlled malaria infection.Journal of immunology (Baltimore, Md. : 1950) · 2013
   Trial
3. ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans.Molecular therapy : the journal of the American Society of Gene Therapy · 2012
   Trial
4. Plasmodium yoelii 17XL infection modified maturation and function of dendritic cells by skewing Tregs and amplificating Th17.BMC infectious diseases · 2020
   Article
5. Host immune response is severely compromised during lethal Plasmodium vinckei infection.Parasitology research · 2015
   Article
6. Cytotoxic activities of CD8⁺ T cells collaborate with macrophages to protect against blood-stage murine malaria.eLife · 2015
   Article
7. Differential immune response associated to malaria outcome is detectable in peripheral blood following Plasmodium yoelii infection in mice.PloS one · 2014
   Article
8. Challenges of assessing the clinical efficacy of asexual blood-stage Plasmodium falciparum malaria vaccines.Human vaccines & immunotherapeutics · 2013
   Review
9. Recombinant viral-vectored vaccines expressing Plasmodium chabaudi AS apical membrane antigen 1: mechanisms of vaccine-induced blood-stage protection.Journal of immunology (Baltimore, Md. : 1950) · 2012
   Article
10. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors.PloS one · 2012
    Article
11. Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors.Molecular therapy : the journal of the American Society of Gene Therapy · 2011
    Article
12. Revealing the molecular signatures of host-pathogen interactions.Genome biology · 2011
    Review
13. Transgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines expressing two alleles of Plasmodium falciparum AMA1.PloS one · 2011
    Article
14. Resistance and Susceptibility to Malarial Infection: A Host Defense Strategy against Malaria.Iranian journal of parasitology
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as